{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The distribution of time to progression will be estimated using the method of Kaplan-Meier and the 3 month progression-free rate (percentage) will be provided. Progression is defined as:\n\nAny one or more of the following: Increase of 25% from lowest value in:\n\n* Serum M-component (absolute increase must be ≥ 0.5 g/dl\n* Serum M-component increase ≥ 1 g/dl, if lowest M component was ≥ 5 g/dl\n* Urine M-component (absolute increase must be ≥ 200 mg/24 h)\n* If at on study, the only measurable non-bone marrow parameter was free light chain (FLC), the difference between involved and uninvolved FLC levels (absolute increase must be \\>10 mg/dl)\n* Bone marrow plasma cell percentage (absolute % must be ≥10%) Or any one or more of the following felt related to the underlying clonal plasma cell proliferative disorder\n* Development of new soft tissue plasmacytomas or bone lesions\n* Hypercalcemia (≥11.5 mg/dl)\n* Decrease in hemoglobin of ≥2 g/dl\n* Serum creatinine level ≥2 mg/dl","groups":[{"description":"Patients receive 100 mg nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 (with 1 week rest). Treatment repeats every 28 days for up to 12 courses/cycles in the absence of disease progression or unacceptable toxicity. After 12 cycles, continued treatment is at the discretion of the investigator until evidence of disease progression. Paclitaxel Albumin-Stabilized Nanoparticle Formulation: Given IV","id":"OG000","title":"Treatment (Chemotherapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Time from registration to the earliest date of documentation of disease progression, assessed up to 3 years","title":"Progression Free Survival at 3 Months","type":"SECONDARY","unitOfMeasure":"percentage of patients"}